Table 3. Pooled diagnostic accuracy.
| Cancer vs. Non-cancer | Tissue-based miRNA | Nor-tissue-based miRNA | Digestive system cancer | Nor-digestive system cancer | |
|---|---|---|---|---|---|
| No. of studies | 13 | 10 | 3 | 4 | 9 |
| Cancer Group (No./total No.) | 211/436 | 165/253 | 46/183 | 79/135 | 132/301 |
| Control Group (No./total No.) | 6/179 | 2/74 | 4/105 | 6/93 | 0/86 |
| OR(95% CI) | 32.80 (11.90–90.37)a | 10.71 (3.48–32.93) | 8.86 (2.93–26.88) | 26.37 (3.21– 216.41)a | 33.97 (11.98– 96.32) |
| Heterogeneityb (p) | 21.41 (0.05) | 14.43 (0.11) | 0.91 (0.63) | 10.82 (0.01) | 9.84 (0.28) |
| AUC (95% CI) | 0.98 (0.96–0.99) | 0.99 (0.98– 1.00) | 0.50 (0.09–0.91) | 0.93 (0.90– 0.95) | 0.50 (0.09– 0.91) |
| SEN (95% CI) | 0.98 (0.89–0.99) | 0.99 (0.76– 1.00) | - | 0.93 (0.84– 0.97) | - |
| Heterogeneityb (p) | 33.16 (0.00) | 16.29 (0.06) | - | 4.15 (0.26) | - |
| SPE (95% CI) | 0.62 (0.39–0.82) | 0.655 (0.36– 0.87) | - | 0.67 (0.30– 0.90) | - |
| Heterogeneityb (p) | 145.83 (0.00) | 113.01 (0.00) | - | 33.5 (0.00) | - |
| PLR(95% CI) | 2.63 (1.44–4.82) | 2.891 (1.29– 6.49) | - | 2.77 (1.00– 7.70) | - |
| Heterogeneityb (p) | 240.04 (0.00) | 242.68 (0.00) | 0.00 (1.0) | 34.61 (0.00) | 0.00 (1.0) |
| NLR(95% CI) | 0.02 (0.002–0.172) | 0.003 (0.00– 0.42) | - | 0.11 (0.04– 0.29) | - |
| Heterogeneityb (p) | 32.93 (0.00) | 35.66 (0.00) | 0.00 (1.0) | 4.61 (0.20) | 0.00 (1.0) |
| DOR(95% CI) | 133.145 (13.21–1341.87) | 1035.07 (7.52–1.4e+05) | - | 25.54 (4.15–157.01) | - |
| Heterogeneityb (p) | 14.537 (0.000) | 14.249 (0.00) | - | 6.24 (0.02) | - |
aSignificant heterogeneity: the random-effects model was chosen to summarize the result; bQ-value.
OR-odds ratio; AUC-area under the curve; SEN-sensitivity; SPE-specificity; PLR-positive likelihood ratio; NLR-negative likelihood ratio; DOR-diagnostic odds ratio.